Competitive Intelligence Accera

Pharmasri—We can provide Company reports, each will be only US$10 only.
www.pharmasri.com
Please contact us at mailto:info@pharmasri.com
Accera, Inc.
COMPANY GENERAL
Address Interlocken Advanced Technology Park

380 Interlocken Crescent
Suite 780
Broomfield, Colorado 80021
TEL 303.999.3700
FAX 303.999.3799
Country U.S.A
Industry Biotechnolgy
Type Private
Therapeutic are Neurology
Web www.accerapharma.com
subsidiary Neuera Pharmaceuticals, Inc.
Highest Phase Phase II
President and CEO Steve Orndorff, Ph.D.

Contact sorndorff@accerapharma.com
Partenering details Accera is currently seeking partners to commercialize

Axona outside the United States.
Seeking business relationships that are collaborative and

allow Accera to participate in both clinical development
and commercialization of partnered product candidates.
Partnering Contat Eric Schauble mail:eschauble@accerapharma.com

1-303-999-3718
PIPELINE ANALYSIS
www.pharmasri.com
Tra
Trial Route of
Drug de Ingredien Syno
Summary Phas Indication adminis Other
Name↑ Na t nym
e tration
me
Axona is al
os being
developed
for Memory
Ketasin ( Axo Caprylictri Phas
Memory - Impairmen - -
Axona) na glyceride e II
Impairmen t
t and is in
preclinical
trials.
Axona is a
prescriptio
n-only
medical
food
intended
for the
clinical
dietary
manageme
nt of the
metabolic Dietary
processes Suppliment
Axo Caprylic Mark PRESCRBI
Axona associated - in mild-to- POWDER
na triglyceride eted NGINFO
with mild- moderate
to- AD
moderate
Alzheimer'
s disease.
In clinical
trials,
Axona has
been
shown to
safely
improve
cognitive
www.pharmasri.com
Tra
Trial Route of
Name↑ Na t nym
e tration
me
function
and
memory in
AD
patients.
Axona
addresses
the
hypometab
olism or
defective
metabolis
m of
glucose
that occurs
in those
areas of
the brain
that are
involved in
Alzheimer’
s disease.
Accera
engages in
research,
developme
nt and
commercia
lization of
other
clinical
application
s for
Axona.
A non Precli Parkinson,s

AC-8632 - - - - -
selective nical disease
www.pharmasri.com
Tra
Trial Route of
Name↑ Na t nym
e tration
me
inhibitor of Drug
both isofor
ms of
acetyl-
coenzyme
Acarboxyla
se that
plays a key
role in
fatty acid
synthesis
ketogenic Ketas Phas Parkinson,s

AC-1202 - - - -
agent yn e II disease
New
chemical
entity,
which Precli
Huntigton,
AC-0523 addresses - - - nical - -
s disease
mitochondr Drug
ial
dysfunctio
n
CLINICAL TRIALS
Study
Phas Dru StudyFirstReceiv Lastupdate
Status↑ Study startdat
e g ed d
e
Ketasyn in Mild to Ketasyn

Complete Phase
Moderate Alzheimer's (AC- 1-Sep-05 30-Dec-08
d II
Disease 1202)
Complete Ketasyn In Age- Phase

Ketasyn 1-Sep-05 30-Dec-08
d Associated Memory II
www.pharmasri.com
Study
Phas Dru StudyFirstReceiv Lastupdate
Status↑ Study startdat
e g ed d
e
Impairment
Safety of Three
Formulations
Complete Phase
of KetasynAdminister Ketasyn 1-Sep-05 30-Dec-08
d I
ed for 14 Days in
Healthy Elderly
FINANCIAL INFO
Date
Title
Announced
Accera announced the culmination of its "Lost & Found" campaign, an online
educational initiative whereby each visit to www.lostandfoundcampaign.com
prompted a donation by Accera to support the Alzheimer's Foundation of
America (AFA).
17-Nov-09
All funds generated through this initiative, which totaled $25,000, are being
donated to AFA today for "National Memory Screening Day" to further the
organization's efforts to support individuals with Alzheimer's disease and their
families.
Accera has recently closed a Series C financing round of $35 million (€ 27

million), led by Inventages Venture Capital SA. Proceeds of this financing will
be used to begin sales and marketing of the company’s lead product, Axona™
(previously known as Ketasyn), which is scheduled to launch in the United
11-Nov-08
States in the first quarter of 2009.
Inventages was joined in this round by San Diego-based POSCO BioVentures
and other previous private investors. Inventages and POSCO participated in the
Company’s Series A and B rounds.
Accera has recently closed a Series B financing round of $7.5 million led by
16-Aug-06
Inventages Venture Capital SA.
Accera has recently closed a Series A financing round of $6 million. The

16-Sep-04 financing was led by inventages Venture Capital GmbH of Geneva, Switzerland
and joined by San Diego-based POSCO BioVentures.
www.pharmasri.com
NEWS ANALYSIS
Date
Type Summary
Realeases
New Evidence Further Validates Ketone Body Therapy as an

Effective Approach in Managing Alzheimer's Disease
Accera announced data which showed that augmentation with
ketone bodies significantly improved cognitive function in
Alzheimer's disease (AD) patients.
An early feature of AD is region specific declines in cerebral
glucose metabolism. One strategy has been to supplement the
brain's normal glucose supply with ketone bodies. The
company's data was drawn from two clinical studies which
examined the cognitive effects of induced ketosis. In both acute
and chronic dosing, AC-1202 (Axona®) significantly induced
ketosis two hours after administration. Further analysis of the
studies revealed that patients administered Axona who lacked
3/9/2010 Clinical Study the epsilon 4 variant of the APOE gene (E4(-)), demonstrated
significant improvement from baseline values in the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog) and
improvement compared to placebo. In the population of
patients who were both APOE4(-) and dosage compliant, more
pronounced improvements in ADAS-cog scores were observed
at each assessment timepoint (Day 45 and Day 90). At Day 45
the improvement in ADAS-cog score relative to Placebo was
6.26 (p=0.001), while at Day 90 the difference was 5.33
(p=0.006). These improvements were remarkable in that they
were seen in patients who were already taking prescription
Alzheimer medications. Many clinicians consider an
improvement greater than 4 points to be clinically significant.
http://www.adi2010.org/default.aspx?pageid=Abstracts
Accera, Inc. to Present at the 3rd Annual European Life Science

CEO Forum for Partnering & Investing
2/1/2010 General Accera will present at the 3rd Annual European Life Science CEO
Forum for Partnering & Investing February 11-12, 2010 at the
ConventionPoint in Zurich, Switzerland.
Tips for Caregivers and a New Therapy Offers Hope in the Fight
Against Alzheimer’s
11/23/2009 General
November is Alzheimer’s Awareness Month. Every 70 seconds
someone in the United States develops Alzheime’s disease, and
www.pharmasri.com
Date
Type Summary
Realeases
the number of cases is expected to double every 20 years. This

devastating and progressive disease not only affects patients,
but also takes a physical toll on the friends and family members
who care for them. Caring for a family member or friend with
Alzheimer’s can be a full time job. If you are caring for someone
with Alzheimer’s, you are not alone—almost 10 million
Americans provide unpaid care for a person with Alzheimer’s
disease or other dementias. In addition to the financial burden
this places on friends and family, caregivers often experience
profound emotional changes such as feelings of loss and grief.
While there is no cure for Alzheimer’s, there are drugs and
medications that target the symptoms. If you or a loved one is
experiencing symptoms of memory loss and disorientation, talk
with your physician about different therapy options. One of the
newest prescription therapies, Axona® provides the brain with
an alternative source of energy. In Alzheimer's patients, brain
cells often do not efficiently use glucose, a main fuel for the
brain, and as a result the cells do not function properly. Axona
works by getting into the cell through other pathways and
provides the cell the fuel it needs to continue functioning.
Available on the market since March 2009, Axona has been
clinically shown to improve cognitive function and memory and
is now showing positive results in Alzheimer’s patients.
Accera, Inc. Announces Culmination of Lost & Found Campaign:

Company Donates $25,000 to the Alzheimer's Foundation of
America for National Memory Screening Day
11/17/2009 Charity Accera announced the culmination of its "Lost & Found"
campaign, an online educational initiative whereby each visit to
www.lostandfoundcampaign.com prompted a donation by
Accera to support the Alzheimer's Foundation of America (AFA).
Accera, Inc. to Present at Lazard Capital Markets 6th Annual

Healthcare Conference
Accera will present at Lazard Capital Markets 6th Annual
Healthcare Conference November 17-18, 2009 at the St. Regis
11/11/2009 Conference
Hotel in New York. Steve Orndorff, Ph.D., founder, president
and CEO, will provide a corporate overview of Accera and an
update on Axona™ on Tuesday, November 17 at 4:10 p.m. EST.
A breakout session will follow Dr. Orndorff’s presentation where
www.pharmasri.com
Date
Type Summary
Realeases
he will be available for questions and answers
Accera, Inc. Awarded “Company of the Year” by the Colorado

BioScience Association
11/11/2009 Award
Accera has been elected as The Colorado Bioscience
Association's 2009 “Company of the Year” Award recipient.
Accera Inc. to Present at UBS Global Life Sciences Conference

9/18/2009 Conference Accera will present at the UBS Global Life Sciences Conference
September 21-23, 2009 in New York.
Accera Announces Peer-Reviewed Publication of the Results of

its 90-day Clinical Study of AC-1202 (Axona™) in Mild to
Moderate Alzheimer’s Disease
Accera announced the publication of a scientific paper in the
peer-reviewed journal Nutrition & Metabolism. The paper,
entitled “Study of the ketogenic agent AC-1202 in mild to
moderate Alzheimer’s disease: a randomized, double-blind,
placebo-controlled, multicenter trial” suggests that daily
administration of AC-1202 (Axona™) can help improve cognition
and memory in patients with mild-to-moderate Alzheimer’s
disease (AD).
The 90-day, randomized, double-blind, placebo-controlled,
parallel-group study, evaluated the effect of daily dosing of AC-
1202 in patients diagnosed with mild-to-moderate Alzheimer’s
Clinical disease. The study was conducted in 152 patients at 23 clinical
8/12/2009
Results sites throughout the United States. The study examined the
effects of AC-1202 on performance in the Alzheimer’s Disease
Assessment Scale – Cognitive subscale (ADAS-Cog). Notably,
participants in the study were allowed to remain on their
current Alzheimer’s disease medications and did not have to
alter their diets in any way. Approximately 80% of the
participants were taking one or more Alzheimer’s disease drugs.
Researchers found that AC-1202 was safe and produced a
beneficial trend for the overall subject population and significant
cognitive benefits in a predefined analysis of patients who did
not carry the epsilon 4 (E4) variant of the apolipoprotein E gene
(APOE4). Possession of an APOE4 allele is the major genetic risk
factor for development of the most common form of Alzheimer’s
disease. In addition, there was a significant correlation between
improvement in cognition and memory and amount of AC-1202
www.pharmasri.com
Date
Type Summary
Realeases
consumed by APOE4(-) patients, i.e., dosing compliance. This

finding suggests that AC-1202 may offer a novel and effective
genotype-specific strategy for Alzheimer’s disease.
Approximately 50% of the general Alzheimer’s disease patient
population is APOE4(-).
Accera, Inc. to Support the Alzheimer’s Foundation of America’s

National Memory Screening Day through On-line Awareness
Effort.
Accera, Inc., a biotechnology company delivering breakthrough
8/11/2009 Charity therapies in central nervous system diseases, announced today
the launch of its “Lost & Found” campaign, an on-line initiative
whereby each visit towww.lostandfoundcampaign.com prompts
a $1 donation by Accera to support the Alzheimer’s Foundation
of America (AFA).
Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of

Directors
Accera announced that Gunnar Weikert, M.D., Ph.D., has been
elected to its board of directors. Dr. Weikert is the Chairman,
CEO and Founder of Inventages Venture Capital. Prior to the
founding of Inventages, he had more than 10 years experience
7/27/2009 Management in a broad spectrum of executive functions in the
pharmaceutical industry culminating as senior vice president
and global head for life sciences transactions at Bayer AG. While
at Bayer, he oversaw venture investments in technology
companies and collaborations representing some of the largest
transactions involving large pharmaceutical and biotechnology
companies in the late 1990s.
Evidence for a New Genetic Link to Therapeutic Efficacy for

Alzheimer’s Disease
Accera announced further evidence for genetic interactions
impacting the efficacy of the ketogenic compound AC-1202
(Axona™) in Alzheimer’s disease. New data from the company’s
Product
7/14/2009 previously completed double-blind, placebo-controlled trial in
Related
patients with mild-to-moderate Alzheimer’s disease
demonstrates an interaction between two genetic markers that
strongly influence the therapeutic response in patients. Dr.
Samuel Henderson, Executive Director of Research, will present
these results at the 2009 International Conference on
www.pharmasri.com
Date
Type Summary
Realeases
Alzheimer’s Disease (ICAD) sponsored by the Alzheimer’s

Association.
During this study, patients received daily administration of
either AC-1202 or placebo for 90 days, with efficacy
assessments performed at Baseline (Day 0), Day 45, Day 90
and after a two week washout from their assigned product on
Day 104. In addition, analyses of a number of genotypic
markers judged to be relevant to the physiological background
of Alzheimer’s disease were also performed.
Previous analysis of the study revealed that patients
administered AC-1202 who lacked the epsilon 4 variant of the
APOE gene (E4(-)), demonstrated significant improvement from
baseline values in the Alzheimer’s Disease Assessment Scale-
Cognitive (ADAS-Cog) and improvement compared to placebo
of 4.77 at Day 45 and 3.36 at Day 90 (p < 0.05). ADAS-Cog, a
neuropsychometric battery of tests that measures short-term
memory and cognition, is probably the most widely used
cognitive instrument used in clinical trials of anti-dementia
drugs within the United States and Europe. Numerous clinical
studies have demonstrated that modest improvements in ADAS-
cog scores – on the order of 2 to 3 points over the course of a
year – have been associated with significant cost reductions in
overall managed care expenditures.
To further investigate pharmacogenomic responses of AC-1202
in AD, the effects of APOE4 carriage status and a polymorphism
(IDE_7) in the insulin degrading enzyme gene (IDE) on ADAS-
Cog scores were evaluated over the study course. In addition to
degrading insulin, the IDE protein also degrades amyloid beta
peptide and has been implicated in playing a role in Alzheimer’s
disease.
In the population of patients who were both APOE4(-) and
lacked the C/C polymorphism in IDE 7, more pronounced
improvements in ADAS-cog scores than those previously
reported were observed at each assessment timepoint (Day 45,
90 and 104). At Day 45 the improvement in ADAS-cog score
was 4.18 (p=0.0004), while at Day 90 the difference was 4.73
(p=0.001). Of interest, a significant difference in cognitive test
scores of 3.27 was observed two weeks after termination of AC-
1202 treatment (p=0.034). This finding suggests that daily
www.pharmasri.com
Date
Type Summary
Realeases
administration of AC-1202 may produce lasting effects in those

patients with this combination of genotypic markers.
The combination of the E4(-); IDE_7(C/C)(-) genotype is
prevalent in approximately 40% of the AD population, so the
number of potential responder patients is substantial.
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

Accera, Inc., a biotechnology company delivering breakthrough
therapies in central nervous system (CNS) diseases, announced
today the formation of Neuera Pharmaceuticals, Inc., a drug
development company. The new company will focus on the
discovery and development of proprietary small molecule drugs
for acute and chronic neurological conditions where the
mechanism of defective energy metabolism or hypometabolism
is involved.
Neuera Pharmaceuticals will operate as a wholly owned
Forming a subsidiary and will be spun out of Accera as a stand-alone
4/15/2009
subsidiary company after the completion of a $12 million series A financing
round. Existing Accera investors have already committed to
participate in the capital raise. Some of Accera’s management
and staff will join the newly formed company, and the current
small molecule pipeline at Accera including the preclinical
compounds, AC-0523 and AC-8632, have been transferred to
Neuera. In addition to in-house development of small
molecules, Neuera Pharmaceuticals is actively pursuing the
license or acquisition of late clinical-stage products for CNS
diseases or conditions that complement the hypometabolism
platform.
Accera, Inc. to Present at Upcoming Investor Conferences

3/25/2009 Conference Accera announced that the company will be participating at two
upcoming healthcare investor conferences.
Dr. Thomas Werner Elected to Accera, Inc.’s Board of Directors

Accera announced that Thomas Werner, Ph.D. has been elected
to its board of directors. Since 2001, Dr. Werner has been a
managing director and senior vice president of GlaxoSmithKline
3/24/2009 Management
(GSK) and has served as CEO of the GSK Foundation until
earlier this year. He led the Pharmaceutical Research
Manufacturers of America (PhRMA) in Germany as its chairman
through November 2008. He began his pharmaceutical career
www.pharmasri.com
Date
Type Summary
Realeases
with Squibb Pharma Germany where he held sales, marketing

and brand management positions from 1983-1989 and later
held executive management positions at Bristol-Myers Squibb.
Dr. Werner earned his Ph.D. in chemistry at the University of
Göttingen in Germany.
Accera Launches Axona™, First Medical Food Therapy to Help

Manage Mild-to-Moderate Alzheimer’s Disease
Accera launched AxonaTM in the United States for Alzheimer’s
disease (AD). Axona is a first-in-class medical food for the
Product
3/2/2009 clinical dietary management of the metabolic processes
Launch
associated with mild-to-moderate Alzheimer’s. Dispensed by
prescription, it targets the metabolic deficiencies and
imbalances associated with AD by providing an alternative
energy source for brain cells.
Accera, Inc. Sponsors Alzheimer’s Association’s 2009 ICAD

Conference
Accera announced that it is a SILVER level sponsor of the 2009
2/19/2009 Conference International Conference on Alzheimer’s Disease (ICAD). The
annual conference, put on by the Alzheimer’s Association, is the
world’s leading forum on dementia research. ICAD 2009 will
take place July 11-16 in Vienna, Austria.
Accera Will Launch Axona, New Approach to Managing

Alzheimer’s Disease, in 2009
Accera will launch AxonaTM in the United States for Alzheimer’s
11/18/2008 Product News
disease (AD) in the first quarter of 2009. The commercial
launch of Axona will be funded by the company’s recent Series
C equity financing.
Accera, Inc. Completes $35 Million Series C Financing

Accera has recently closed a Series C financing round of $35
million (€ 27 million), led by Inventages Venture Capital SA.
11/11/2008 Finance Proceeds of this financing will be used to begin sales and
marketing of the company’s lead product, Axona™ (previously
known as Ketasyn), which is scheduled to launch in the United
States in the first quarter of 2009.
Accera, Inc. to Present at BIO CEO & Investor Conference

2/7/2008 Conference Accera announced that Dr. Steve Orndorff, Accera’s president
and CEO, will be presenting at the BIO CEO & Investor
www.pharmasri.com
Date
Type Summary
Realeases
Conference on February 12 at 3:30 p.m. EST at the Waldorf-

Astoria in New York City.
Accera, Inc. to Present at Rodman & Renshaw 9th Annual

Healthcare Conference
Accera Inc. announced today that the company will be
11/2/2007 Conference participating in the Rodman & Renshaw 9th Annual Healthcare
Conference November 5-7 at the Palace Hotel in New York City.
President and CEO Dr. Steve Orndorff will present the company
November 7 at 12:40 p.m. in the Hubbard Room.
William Poncy Appointed as Vice President, Commercial

Development
Accera, Inc. has appointed William T. Poncy, M.B.A., as Vice
President of Commercial Development. He will direct the
commercial launch of Ketasyn (AC-1202) as a medical food
product in the U.S. for the treatment of Alzheimers' disease and
the development of the ethical drug franchise for
neurodegenerative diseases at Accera.
Accera, Inc. to Present at the 4th Annual BIO Investor Forum

Accera Inc., a privately held biotechnology company focused on
developing novel drugs for neurodegenerative diseases,
10/4/2007 Conference
announced today that the company will be participating in the
4th Annual BIO Investor Forum next week at the Palace Hotel in
San Francisco
Ketasyn Improves Memory in Age-Associated Memory

Impairment Study
A double-blind, placebo-controlled Phase II study with 159
subjects characterized with Age-Associated Memory Impairment
showed that Ketasyn (AC-1202) has a positive and clinically
8/29/2007 Product news
meaningful effect on memory in older adults. The study results
were consistent with earlier Phase II studies done with
Alzheimer's disease patients, particularly those with the
APOE4(-) genotype who showed significant improvement in
memory and cognition.
Experimental Drug Ketasyn (AC-1202) Treats Alzheimer's as

Diabetes of the Brain
6/26/2007 Product news
Accera, Inc. announced today that recent data from its Phase
IIb study in Alzheimer's disease (AD) support findings showing
www.pharmasri.com
Date
Type Summary
Realeases
that AD may effectively be thought of and treated as diabetes of

the brain.
Accera, Inc. Announces Open-Label Data from Phase II Study in

Alzheimer's Disease at International Conference on Prevention
of Dementia
All subjects who were treated with AC-1202 during the full nine
months of the double-blinded and open-label phases of the
6/11/2007 Clinical results clinical trial showed very little disease progression. Patients with
the ApoE4(-) genotype who started taking AC-1202 for the first
time during the open-label extension showed significant
improvement in memory and cognition. This result was
consistent with the double-blinded phase of this study as well as
an earlier Phase IIa clinical study.
Accera, Inc. to Present at Upcoming Investor Conferences

Accera, Inc. announced today that the company will participate
in three upcoming healthcare investor conferences, Dr. Steve
5/8/2007 Conference Orndorff, President and CEO, will make presentations about the
business of the company, its technology platform and the recent
positive data from a Phase IIb study of AC-1202 for Alzheimer's
disease.
Accera announced the line results of a Phase IIb clinical study of

its lead compound, AC-1202, in 152 patients diagnosed with
mild-to-moderate Alzheimer's disease. The multi-center trial,
conducted in the U.S., was designed as a double-blinded,
Clinical placebo-controlled study over 104 days, followed by a six
5/4/2007
Results month open-label extension phase. Signficant efficacy was
observed in those patients treated with AC-1202, particularly in
those with the ApoE4(-) genotype and one other
pharmacogenomic marker that is involved in brain energy
metabolism.
Accera Presents Phase IIb Clinical Data at American Academy of

Neurology
Accera announced today that the line data from its Phase IIb
4/24/2007 Presentation study of its lead compound, AC-1202, in Alzheimer's disease will
be presented at the annual meeting of the American Academy
of Neurology in Boston by Dr. Lauren Costantini, Vice President
of Clinical Development.
www.pharmasri.com
Date
Type Summary
Realeases
Accera Participates in Neurotechnology Industry Organization

Public Policy Tour
Accera executive management participated in a public policy
tour with the Neurotechnology Industry Organization (NIO) that
met with the FDA, NIH and elected members of Congress to
4/3/2007 Conference discuss opportunities and obstacles facing companies in the
development of new therapies for diseases of the central
nervous system. During the tour NIO promoted the concept of a
National Neurotechnology Initiative with a federal National
Coordination Office to direct existing multi-agency efforts in
neurotechnology. Accera is a founding member of NIO.
Accera Enters Product Development Agreement with Nestle

Purina PetCare
Accera, Inc. announced today an agreement under which it has
1/8/2007 Deals&alliance granted Nestle Purina PetCare Global Resources, Inc. the right
to develop its proprietary compound, AC-1203, for application
to healthy aging and wellness in dogs and other companion
animals.
Accera Initiates Phase 2 Trial in Age Associated Memory

Impairment
Accera, Inc., a drug development company focused on
8/8/2006 Clinical trial Alzheimer's disease and related neurodegenerative diseases,
announced it has initiated a multi-center, placebo-controlled
Phase IIa study of KetasynTM (AC-1202) for the treatment of
Age Associated Memory Impairment (AAMI).
Accera Completes $ 7.5 Million Series B Financing

Accera, Inc., a drug development company focused on
8/16/2006 Finance Alzheimer's disease and related neurodegenerative diseases,
announced it has recently closed a Series B financing round of
$7.5 million led by Inventages Venture Capital SA.
Accera Names Lauren C. Costantini, Ph.D., as Vice President,

Clinical Development
Accera announced today the appointment of Lauren C.
Costantini, Ph.D., as Vice President of Clinical Development.
She has a distinguished career in neuroscience with experience
in all phases of clinical development from research to Phase III
clinical trials for therapeutic products ranging from chronic pain
and opioid dependency to spinal cord injury and Parkinson's
www.pharmasri.com
Date
Type Summary
Realeases
disease. Most recently she was Director of Product Development

at Titan Pharmaceuticals and previously was on the faculty at
Harvard Medical School.
Accera Researchers Demonstrate That a Low-Carbohydrate,

High-Fat DIet Reduced Markers of Alzheimer's Disease in a
Transgenic Mouse Model
Accera announced that company researchers have
10/17/2005 Research
demonstrated that an extremely low-carbohydrate, high-fat
diet, known as a "ketogenic diet" reduced levels of the amyloid
beta peptide in a transgenic mouse model of Alzheimer's
disease (AD).
Accera Expands Ongoing KetasynTM Clinical Trial for

Alzheimer's Disease
Accera, Inc. announced today that it has received approval to
9/8/2005 Product News
provide Alzheimer's disease patients in its' ongoing Phase IIb
clinical trial the opportunity to receive KetasynTM (AC-1202)
treatment in a formal open label six-month extension study.
Accera Establishes Clinical and Scientific Advisory Boards for Its

Pioneering Approach to Alzheimer's Disease
Accera announced the formation of a Clinical Advisory Board
(CAB) and Scientific Advisory Board (SAB) to assist in the
12/14/2004 General
Company's product development efforts. Accera is developing a
new class of therapeutic products to treat or prevent
Alzheimer's disease (AD) and related neurodegenerative
diseases that are often associated with aging.
Accera Names Gary Hooper as Board Member

Accera announced the appointment of Gary Hooper to its Board
12/9/2004 Management of Directors. Mr. Hooper has nearly twenty years of executive
management level experience in the biotechnology industry and
broad experience in corporate and business development.
Claude H. Nash Joins Accera, Inc. as Chairman of the Board

Accera announced the appointment of Claude H. Nash, Ph.D. to
Chairman of the Board. Dr. Nash has been a leading figure in
the biotechnology industry as President of ViroPharma, Inc. He
brings to Accera more than 20 years of executive management
experience in the pharmaceutical and biotechnology industries.
9/16/2004 Finance Accera Completes $6 Million Series A Financing

www.pharmasri.com
Date
Type Summary
Realeases
Accera has recently closed a Series A financing round of $6

million. The financing was led by inventages Venture Capital
GmbH of Geneva, Switzerland and joined by San Diego-based
POSCO BioVentures.
MANAGEMENT
Name Position mail Summary
Steve Orndorff is a serial

entrepreneur with more than
25 years experience in the
biotechnology industry.
Previously he was President
and CEO of Univera
Pharmaceuticals, Inc., a drug
discovery company focused
on diseases of inflammation
and the immune response.
During his career he has had
responsibility in a broad
Founder, array of disciplines such as
President and basic research,
Steve A. mail:
Chief manufacturing, product
Orndorff, Ph.D. sorndorff@accerapharma.com
Executive development and business
Officer development at various
biotechnology companies
including Genex Corporation,
NutraSweet, Inc., and
ZeaGen, Inc. Dr. Orndorff is
a past President of the
Society for Industrial
Microbiology and a founding
Board member of the
Colorado BioScience
Association. He received a
B.S. in Biology from Virginia
Tech and a Ph.D. in
www.pharmasri.com
microbiology from University

of Maryland.
William brings more than 25

years of experience in the
pharmaceutical industry to
Accera. He has a
demonstrated track record of
success in all aspects of the
pharmaceutical commercial
organization. Prior to joining
Accera in 2007, he was Vice
President of Sales and
Marketing for Myogen, Inc.
(acquired by Gilead Sciences)
where he built the
commercial organization and
launched a pulmonary anti-
hypertension franchise.
Vice Previously he was Vice
William T. President, President of Sales and
Poncy, M.B.A. Commercial Marketing, North America for
Development Pharmion where he
developed an oncology
commercial organization. He
started his career in field
sales with Berlex Labs and
then from 1982 until 2000,
William held several positions
at DuPont Pharmaceuticals
including sales, managed
care, trade, marketing,
public policy and various
management roles. Bill
received his B.S. in Biological
Science from the University
of California, Irvine and his
M.B.A. from the University of
Phoenix.
Samuel Vice Samuel Henderson's research

www.pharmasri.com
Henderson, President, has defined new pathways in

Ph.D. Research & the understanding of
Development neurodegenerative diseases,
such as Alzheimer's disease.
Most recently, Dr. Henderson
was at The Institute of
Behavioral Genetics,
University of Colorado,
Boulder, CO where he
investigated the genetics of
aging. Prior to that, he was a
Lead Scientist at GenoPlex,
Inc. directing research in
anti-aging technologies. Dr.
Henderson has co-authored
numerous scientific
publications, patents and
reviews, including
fundamental discoveries in
aging research. He received
his B.A. in Biology from
Washington University, St.
Louis, MO and his Ph.D. in
Molecular Genetics and Cell
Biology from University of
Chicago. He received
extensive post-doctoral
training in developmental
biology at the University of
Wisconsin. Dr. Henderson is
the scientific founder of
Accera.
Gregory Kading has over 20

years experience in finance
Gregory Vice and accounting in a variety
Kading, CFA, President, of positions with US West
M.B.A. Finance (now Qwest
Communications), including
accounting operations,
www.pharmasri.com
financial planning and

analysis, financial modeling,
business planning and
corporate investment
analysis. Most recently he
was Director of Finance for
the Broadband Services unit
of Qwest. He has been a
financial consultant for
numerous start-up
companies and has been an
adjunct instructor at Metro
State College of Denver and
Arapahoe Community
College. Greg was awarded
the Chartered Financial
Analyst designation from the
CFA Institute. An Iowa
native, Greg holds a B.S. in
Industrial Engineering from
Iowa State University, and
an M.B.A. degree from
Creighton University.
Dr. Nash brings to Accera

more than 20 years of
executive management
experience in the
pharmaceutical and
biotechnology industries.
Claude Nash is currently the
Claude H. President and CEO of
Chairman
Nash, Ph.D. Bloodstone Ventures plc.
Previously he was the
founder, CEO, and chairman
of ViroPharma Inc. where he
oversaw the development of
several antiviral drugs,
successfully raised $430M in
capital and achieved a $1.2B
www.pharmasri.com
market capitalization for the

company following its Initial
Public Offering. Prior to
founding ViroPharma, Dr.
Nash was Vice President of
infectious disease and cancer
research at the Schering-
Plough Research Institute
where he initiated new
strategic technologies for
drug discovery and advanced
three new drugs into
development. Throughout his
career he has managed the
research and development of
more than twenty drugs in
the areas of infectious
diseases, cancer,
hypertension and pain. In the
past he worked for several
large pharmaceutical
companies including Sterling-
Winthrop, Smith Kline &
French, and Eli Lilly. He is
currently a director of Adolor,
Inc. Dr. Nash earned his
Ph.D. degree in microbial
genetics and biochemistry
from Colorado State
University.
Mr. Hooper has nearly twenty

years of executive
management level
experience in the
Gary Hooper Director biotechnology industry and
broad experience in
corporate and business
development. Gary was
recently Vice President of
www.pharmasri.com
Business Development for

Bioproducts at Genencor
International. He previously
served as President and CEO
of Ciblex Corporation, a
biotech company developing
therapeutic drugs for
inflammatory diseases
through inhibition of cell-to-
cell communication. He has
held a number of executive
and senior management
positions at Cygnus
Therapeutic Systems,
Genentech and Baxter
Travenol. Gary is on the
Board of Directors for the
University of Southern
California, Scientific Advisory
Council at the University of
Utah, Board of Directors of
Joint Venture: Silicon Valley
Network, Board of Trustees
for the Licensing Executives
Society and executive
member of the Health Care
Committee, and Chairman of
Silicon Valley's Technology
Convergence Consortium. He
received an M.B.A. degree in
management from the
University of Southern
California.
Dr. Orndorff is the founder,

President and CEO of Accera,
Steve A. Inc. He has more than 25
Director
Orndorff, Ph.D. years experience in the
biotechnology industry.
Previously he was President
www.pharmasri.com
and CEO of Univera

Pharmaceuticals, Inc., a
privately-held drug discovery
company focused on diseases
of inflammation and the
immune response. During his
career he has had
responsibility in a broad
array of disciplines such as
basic research,
manufacturing, product
development and business
development at various
biotechnology companies
including Genex Corporation,
NutraSweet, Inc., and
ZeaGen, Inc. Dr. Orndorff is
a past President of the
Society for Industrial
Microbiology and a founding
board member of the
Colorado BioScience
Association. He received a
Ph.D. in microbiology from
the University of Maryland.
Dr. Reichenberger has many

years of financial and
experience in the food and
nutrition industry. During a
29 year career at the world's
Wolfgang
largest food company, Nestle
Reichenberger, Director
SA, he led different functions
Ph.D.
and overall operations in
Europe, Asia, Oceania, and
North and South America.
Recently he was Executive
Vice President and Chief
Financial Officer of Nestle SA,
www.pharmasri.com
and he served on the

governing admission body at
the Swiss Stock Exchange.
Currently he is Founder and
General Partner of
Inventages WHealth
Management Inc. and IVC
Americas SA. Dr.
Reichenberger serves on the
Board of Directors for several
U.S. and European
biotechnology companies. He
earned a Masters of Business
Administration from
Hochschule St. Gallen and a
Ph.D. in Business
Administration from
Wirtschaftsuniversitaet Wien.
Dr. Weikert is the Chairman,

CEO and Founder of
Inventages Venture Capital.
Prior to the founding of
Inventages, he had more
than 10 years experience in
a broad spectrum of
executive functions in the
pharmaceutical industry
Gunnar culminating as senior vice
Weikert, M.D., Director president and global head for
Ph.D., MBA life sciences transactions at
Bayer AG. While at Bayer, he
oversaw venture investments
in technology companies and
collaborations representing
some of the largest
transactions involving large
pharmaceutical and
biotechnology companies in
the late 1990s. Dr. Weikert
www.pharmasri.com
received his M.D. from the

University of Düsseldorf and
his Ph.D. in the field of
metabolism from the
Diabetes Research Center in
Germany. He also holds an
MBA.
Dr. Werner was elected as an

independent director to the
Board of Directors in March,
2009. Since 2001, Dr.
Werner has been a managing
director and senior vice
president of GlaxoSmithKline
(GSK) and has served as
CEO of the GSK Foundation
until earlier this year. He led
the Pharmaceutical Research
Manufacturers of America
(PhRMA) in Germany as its
chairman through November
2008. He began his
Thomas pharmaceutical career with
Director
Werner, Ph.D. Squibb Pharma Germany
where he held sales,
marketing and brand
management positions from
1983-1989 and later held
positions at Bristol-Myers
Squibb, including Managing
Director for Convatec
Germany and Bristol
Arzneimittel Oncology. Dr.
Werner co-founded the
Genetic Research Center, a
joint venture with the Max
Planck Institute for
Psychiatry and the Ludwig-
www.pharmasri.com
Maximilians-University, both
in Munich. He is a member of
the Board of Trustees of the
Paul Ehrlich Association and
the Robert Koch Foundation.
Dr. Werner earned his Ph.D.
in chemistry at the University
of Göttingen in Germany.
Dr. Steven H. Ferris is

Chairman of the Accera
Clinical Advisory Board, a
Gerald & Dorothy Friedman
Professor of the New York
University Alzheimer's
Disease Center, and
Executive Director of the
Silberstein Institute for Aging
and Dementia at the NYU
School of Medicine. In this
capacity he leads a staff of
30 persons that have
conducted more than 40
sponsored clinical drug trials
Steven H.
Advisory in aging and Alzheimer's
Ferris, Ph.D.
disease (AD). Dr. Ferris is a
recognized leader in the
development of
neuropsychometric tests for
memory and cognition that
are used worldwide for
clinical testing of AD drugs
and approval by regulatory
agencies. During his
distinguished career he has
authored more than 175
scientific publications and
served on the editorial
boards of numerous journals
on aging and dementia. Dr.
www.pharmasri.com
Ferris was awarded a Ph.D.

in Experimental Psychology
by City University of New
York.
Dr. Martin R. Farlow is Vice

Chairman of Research and
Professor in Neurology at the
Indiana University School of
Medicine, and Director of the
Clinical Core of the
Alzheimer's Disease Clinic.
His clinical research focuses
primarily on Alzheimer's
disease, therapeutic
treatments for various
dementias, and effective
diagnosis of memory and
cognitive loss secondary to
Alzheimer's disease. Dr.
Martin R. Farlow has conducted greater
Advisory
Farlow, M.D. than 100 clinical trials in
Alzheimer's disease and
other dementias. He is a
highly regarded lecturer on
the treatment and care of
patients with Alzheimer's
disease. His research has led
to more than 250
publications and he currently
serves on the editorial
boards of numerous journals
related to aging, dementia
and research. Dr. Farlow
received his medical
education at Indiana
University.
Dr. Leif Hertz is Professor

Leif Hertz,
Advisory Emeritus in the Department
M.D., D.Sc.
of Pharmacology at
www.pharmasri.com
University of Saskatchewan.
He is an expert on energy
metabolism in the brain,
neuronal-astrocytic
interactions and the
biochemical characteristics of
memory formation. Dr. Hertz
has more than 320 scientific
publications and has served
on the editorial boards of five
prestigious journals of
neuroscience. He has held
continuous grants from the
Medical Research Council of
Canada and has received
numerous awards for his
achievements in
neurochemistry research. Dr.
Hertz received his M.D. from
University of Copenhagen
and D.Sc. from University of
Odense.
PATENTS GRANTED
Sno Patent Title
Use of medium chain triglycerides for the treatment and prevention of

1 6,835,750 alzheimer's disease and other diseases resulting from reduced neuronal
metabolism II
PATENTS APPLIED
Patent Appl
Sno Title
Number
Method to Reduce Oxidative Damage and Improve Mitochondrial

1 20100041751
Efficiency
www.pharmasri.com
Patent Appl
Sno Title
Number
2 20100003730 Enzymatic Synthesis of Acetoacetate Esters and Derivatives
Use of Ketogenic Compounds for Treatment of Age-Associated Memory

3 20080287372
Impairment
COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND

THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF
4 20080009467
ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM
REDUCED NEURONAL METABOLISM
COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING

5 20070179197
BRAIN FUNCTION
METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE

6 20070135376
MITOCHONDRIAL EFFICIENCY
Drug targets for alzheimer's disease and other diseases associated

7 20030059824
with decreased neuronal metabolism
Contact us at info@pharmasri.com

Competitive Intelligence Accera

Încărcat de

Informații document

Descriere originală:

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Competitive Intelligence Accera

Încărcat de

Drepturi de autor:

Formate disponibile

Pharmasri—We can provide Company reports, each will be only US$10 only.

Address Interlocken Advanced Technology Park

President and CEO Steve Orndorff, Ph.D.

Partenering details Accera is currently seeking partners to commercialize

Seeking business relationships that are collaborative and

Partnering Contat Eric Schauble mail:eschauble@accerapharma.com

A non Precli Parkinson,s

ketogenic Ketas Phas Parkinson,s

Ketasyn in Mild to Ketasyn

Complete Ketasyn In Age- Phase

Accera has recently closed a Series C financing round of $35 million (€ 27

Accera has recently closed a Series A financing round of $6 million. The

New Evidence Further Validates Ketone Body Therapy as an

Accera, Inc. to Present at the 3rd Annual European Life Science

the number of cases is expected to double every 20 years. This

Accera, Inc. Announces Culmination of Lost & Found Campaign:

Accera, Inc. to Present at Lazard Capital Markets 6th Annual

he will be available for questions and answers

Accera, Inc. Awarded “Company of the Year” by the Colorado

Accera Inc. to Present at UBS Global Life Sciences Conference

Accera Announces Peer-Reviewed Publication of the Results of

consumed by APOE4(-) patients, i.e., dosing compliance. This

Accera, Inc. to Support the Alzheimer’s Foundation of America’s

Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of

Evidence for a New Genetic Link to Therapeutic Efficacy for

Alzheimer’s Disease (ICAD) sponsored by the Alzheimer’s

administration of AC-1202 may produce lasting effects in those

Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

Accera, Inc. to Present at Upcoming Investor Conferences

Dr. Thomas Werner Elected to Accera, Inc.’s Board of Directors

with Squibb Pharma Germany where he held sales, marketing

Accera Launches Axona™, First Medical Food Therapy to Help

Accera, Inc. Sponsors Alzheimer’s Association’s 2009 ICAD

Accera Will Launch Axona, New Approach to Managing

Accera, Inc. Completes $35 Million Series C Financing

Accera, Inc. to Present at BIO CEO & Investor Conference

Conference on February 12 at 3:30 p.m. EST at the Waldorf-

Accera, Inc. to Present at Rodman & Renshaw 9th Annual

William Poncy Appointed as Vice President, Commercial

Accera, Inc. to Present at the 4th Annual BIO Investor Forum

Ketasyn Improves Memory in Age-Associated Memory

Experimental Drug Ketasyn (AC-1202) Treats Alzheimer's as

that AD may effectively be thought of and treated as diabetes of

Accera, Inc. Announces Open-Label Data from Phase II Study in

Accera, Inc. to Present at Upcoming Investor Conferences

Accera announced the line results of a Phase IIb clinical study of

Accera Presents Phase IIb Clinical Data at American Academy of

Accera Participates in Neurotechnology Industry Organization

Accera Enters Product Development Agreement with Nestle

Accera Initiates Phase 2 Trial in Age Associated Memory

Accera Completes $ 7.5 Million Series B Financing

Accera Names Lauren C. Costantini, Ph.D., as Vice President,

disease. Most recently she was Director of Product Development

Accera Researchers Demonstrate That a Low-Carbohydrate,

Accera Expands Ongoing KetasynTM Clinical Trial for

Accera Establishes Clinical and Scientific Advisory Boards for Its

Accera Names Gary Hooper as Board Member

Claude H. Nash Joins Accera, Inc. as Chairman of the Board

9/16/2004 Finance Accera Completes $6 Million Series A Financing

Accera has recently closed a Series A financing round of $6

Name Position mail Summary

Steve Orndorff is a serial